文献速递特殊人群用药治疗药物监测与药物基因组学

儿童实体器官与造血干细胞移植受者中更昔洛韦与缬更昔洛韦的群体药代动力学

Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.
PubMed 文献 · Br J Clin Pharmacol · 2021-01-19

按体重给药的静脉更昔洛韦或口服缬更昔洛韦达到AUC0-24h 40-60 mg·h·L-1目标的概率均较低(最高约33%),提示治疗药物监测可能有助于优化暴露。

要点

  • 儿童移植受者中更昔洛韦清除率受肌酐清除率和体重显著影响。
  • 静脉更昔洛韦15-20 mg·kg-1·d-1分每12小时给药,目标达成概率仅33.0-33.8%。
  • 口服缬更昔洛韦按年龄分层给药的目标达成概率为29.1-33.0%,提示需治疗药物监测。

核心结论

  • 这是首个在儿童实体器官移植或造血干细胞移植受者中建立的更昔洛韦/缬更昔洛韦群体药代动力学模型。
  • 按体重给药的静脉更昔洛韦或口服缬更昔洛韦达到替代疗效目标(AUC0-24h 40-60 mg·h·L-1)的概率较低,提示治疗药物监测可能有助于确保最佳暴露。

研究设计与样本

  • 使用非线性混合效应模型(NONMEM)进行分析,最优剂量基于达到替代疗效目标AUC0-24h 40-60 mg·h·L-1的概率确定。

主要发现

  • 二室模型 with 一级吸收(含滞后时间)和一级消除能良好拟合数据。
  • 肌酐清除率和体重是更昔洛韦清除率的显著协变量,体重也是分布容积的显著协变量。
  • 静脉更昔洛韦15-20 mg·kg-1·d-1分每12小时给药,目标达成概率最高为33.0-33.8%。
  • 口服缬更昔洛韦在0-<6岁儿童30 mg·kg-1·d-1、6-18岁儿童40 mg·kg-1·d-1分每12小时给药,目标达成概率最高为29.1-33.0%。

关键数值与推荐

  • 替代疗效目标为更昔洛韦24小时血药浓度-时间曲线下面积(AUC0-24h)40-60 mg·h·L-1。
  • 静脉更昔洛韦推荐剂量15-20 mg·kg-1·d-1分每12小时给药,目标达成概率33.0-33.8%。
  • 口服缬更昔洛韦在0-<6岁儿童30 mg·kg-1·d-1、6-18岁儿童40 mg·kg-1·d-1分每12小时给药,目标达成概率29.1-33.0%。

临床怎么用

  • 儿童移植受者按体重给予静脉更昔洛韦或口服缬更昔洛韦时,达到目标暴露的概率较低,临床应考虑进行治疗药物监测以优化剂量。
  • 处方时应关注患儿的肌酐清除率和体重,这些因素显著影响更昔洛韦的清除率和分布容积。

局限性

  • 目标达成概率基于替代疗效目标AUC0-24h 40-60 mg·h·L-1,并非直接临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Ganciclovir (GCV) and its prodrug valganciclovir (VGCV) are first-line agents to prevent and treat cytomegalovirus in transplant recipients. There is high pharmacokinetic (PK) interindividual variability and PK data are scarce, especially in paediatric stem cell transplant (SCT) recipients. We sought to determine the optimal GCV and VGCV dosing in transplanted children. METHODS: We conducted a single-centre retrospective population PK (POPPK) study of IV GCV and enteral VGCV in paediatric solid organ transplant (SOT) and SCT recipients. We included children who were transplanted and had available plasma GCV concentrations, done per standard of care. POPPK analysis was performed using a nonlinear mixed effects modelling approach with NONMEM. Optimal dosing was determined based on the achievement of the surrogate efficacy target: GCV 24 h area under the concentration-time curve (AUC0-24h ) of 40-60 mg.h.L-1 . RESULTS: Fifty children with a median [range] age of 7.5 years [0.5-17.4] contributed 580 PK samples. A two-compartment model with first-order absorption with a lag time and first-order elimination fit the data well. Creatinine clearance and body weight (WT) were significant covariates for GCV clearance (CL); and WT for the volumes of distribution. IV GCV 15-20 mg.kg-1 .day-1 divided every 12 hours achieved the highest probability of target achievement (PTA) (33.0-33.8%). Enteral VGCV 30 and 40 mg.kg-1 .day-1 divided every 12 hours in children 0-<6 years, and 6-18 years, respectively, achieved the highest PTA (29.1-33.0%). CONCLUSION: This is the first POPPK model developed in children with either SOT or SCT. Concentration target achievement was low, suggesting a potential benefit for therapeutic drug monitoring to ensure optimal exposure.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Franck B, Woillard JB, Théorêt Y, et al. Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients. Br J Clin Pharmacol. 2021. PMID: 33373493. doi:10.1111/bcp.14719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。